Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence

Journal of Substance Abuse Treatment

Volumn 47, Issue 4, 2014, Pages 275-281

  Hämmig, Robert ^a   Köhler, Wilfried ^b   Bonorden Kleij, Karin ^c   Weber, Bernd ^d   Lebentrau, Karin ^e   Berthel, Toni ^f   Babic Hohnjec, Lucija ^f   Vollmert, Christian ^g   Höpner, Doris ^h   Gholami, Najibulah ^i,j   Verthein, Uwe ^k   Haasen, Christian ^k   Reimer, Jens ^k   Ruckes, Christian ^l  

^a Psychiatrische Universitatsklinik   (Switzerland)

^b Burgerhospital Frankfurt am Main   (Germany)

^c Asklepios Klinik Nord Heidberg   (Germany)

^d Private practice   (Germany)

^e Private Practice   (Germany)

^f Integrierte Psychiatrie Winterthur Ipw   (Switzerland)

^g CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^h Private Internal Medicine Practice   (Germany)

ⁱ UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^j Mainstation Center   (Switzerland)

^k UNIVERSITY OF HAMBURG   (Germany)

^l UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

Opioid dependence; Opioid substitution treatment; QTc interval; Safety; Slow release oral morphine

Indexed keywords

BENZODIAZEPINE DERIVATIVE; METHADONE; MORPHINE SULFATE; MUNDIPHARMA; PREGABALIN; SEVRE LONG; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; MORPHINE;

ADULT; AGITATION; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS HEMORRHAGE; FATIGUE; FEMALE; HEART; HUMAN; HYPERHIDROSIS; INSOMNIA; LIBIDO DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL STRESS; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; OPIATE ADDICTION; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; SLOW RELEASE FORMULATION; SOMNOLENCE; TREATMENT DURATION; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; EUROPE; INTERNATIONAL COOPERATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; METHADONE; MORPHINE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84906045967     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.05.012     Document Type: Article

References (40)

1. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28:321-329.
2. Bart G. Maintenance medication for opiate addiction: The foundation of recovery. Journal of Addictive Diseases 2012, 31:207-225.
3. Bazett H.C. An analysis of the time-relations of electrocardiograms. Annals of Noninvasive Electrocardiology 1997, 2:177-194.
4. Beck T., Haasen C., Verthein U., Walcher S., Schuler C., Backmund M., et al. Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone. Addiction 2014, 109:617-626.
5. Bent S., Padula A., Avins A.L. Brief communication: Better ways to question patients about adverse medical events: A randomized, controlled trial. Annals of Internal Medicine 2006, 144:257-261.
6. Carrieri M.P., Roux P., Cohen J., Ravaux I., Dellamonica P., Protopopescu C., et al. Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: Results from the MANIF 2000 cohort study. Addiction 2010, 105:2160-2168.
7. Chou R., Weimer M.B., Dana T. Methadone overdose and cardiac arrhythmia potential: Findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence Clinical Practice Guideline. The Journal of Pain 2014, 15:338-365.
8. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment 2007, 11:1-171. (iii-iv).
9. Deshpande P.R., Rajan S., Sudeepthi B.L., Abdul Nazir C.P. Patient-reported outcomes: A new era in clinical research. Perspectives in Clinical Research 2011, 2:137-144.
10. Downing R.W., Rickels K., Meyers F. Side reactions in neurotics: I. A comparison of two methods of assessment. The Journal of Clinical Pharmacology 1970, 10:289-297.
11. Dyer K.R., White J.M. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997, 92:1445-1455.
12. Eder H., Jagsch R., Kraigher D., Primorac A., Ebner N., Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 2005, 100:1101-1109.
13. EMCDDA (European Monitoring Centre for Drugs, Drug Addiction) European Drug Report 2013: Trends and Developments (Accessed 10 July 2013). http://www.emcdda.europa.eu/publications/edr/trends-developments/2013.
14. EU Action Plan on Drugs Retrieved from. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:351:0001:0023:en:PDF.
15. Falcato L., Beck T., Reimer J., Verthein U. Self-reported cravings for heroin and cocaine during maintenance treatment with slow release oral morphine compared to methadone: A randomized cross-over clinical trial. Journal of Clinical Psychopharmacology 2014.
16. Ferri M., Minozzi S., Bo A., Amato L. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database of Systematic Reviews 2013, 6:CD009879.
17. Hardt J., Egle U.T., Kappis B., Hessel A., Brähler E. Symptom Checklist SCL-27. Psychotherapie Psychosomatik Medizinische Psychologie 2004, 54:214-223. (Article in German).
18. Jegu J., Gallini A., Soler P., Montastruc J.L., Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: A systematic review. British Journal of Clinical Pharmacology 2011, 71:832-843.
19. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. The New England Journal of Medicine 2000, 343:1290-1297.
20. Kastelic A., Dubajic G., Strbad E. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 2008, 103:1837-1846.
21. Katchman A.N., McGroary K.A., Kilborn M.J., Kornick C.A., Manfredi P.L., Woosley R.L., et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. Journal of Pharmacology and Experimental Therapeutics 2002, 303:688-694.
22. Krantz M.J., Kutinsky I.B., Robertson A.D., Mehler P.S. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003, 23:802-805.
23. Kreek M.J. Medical safety and side effects of methadone in tolerant individuals. Journal of the American Medical Association 1973, 223:665-668.
24. Langrod J., Lowinson J., Ruiz P. Methadone treatment and physical complaints: A clinical analysis. The International Journal of the Addictions 1981, 16:947-952.
25. Maremmani I., Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment. The American Journal on Addictions 2010, 19:557-568.
26. Maremmani I., Pani P.P., Pacini M., Bizzarri J.V., Trogu E., Maremmani A.G., et al. Subtyping patients with heroin addiction at treatment entry: Factor derived from the Self-Report Symptom Inventory (SCL-90). Annals of General Psychiatry 2010, 9:15.
27. Mattick R.P., Ali R., White J.M., O'Brien S., Wolk S., Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003, 98:441-452.
28. Mattick R.P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews (Online) 2014, 6(2):CD002207.
29. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
30. Petitjean S., Stohler R., Déglon J.J., Livoti S., Waldvogel D., Uehlinger C., et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence 2001, 62:97-104.
31. Sheftell F.D., Feleppa M., Tepper S.J., Rapoport A.M., Ciannella L., Bigal M.E. Assessment of adverse events associated with triptans-Methods of assessment influence the results. Headache 2004, 44:978-982.
32. Stringer J., Welsh C., Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. American Journal of Health-System Pharmacy 2009, 66:825-833.
33. Sturm S., Hammann F., Drewe J., Maurer H.H., Scholer A. An automated screening method for drugs and toxic compounds in human serum and urine using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2010, 878:2726-2732.
34. Sussner B.D., Smelson D.A., Rodrigues S., Kline A., Losonczy M., Ziedonis D. The validity and reliability of a brief measure of cocaine craving. Drug and Alcohol Dependence 2006, 83:233-237.
35. Tiffany S.T., Singleton E., Haertzen C.A., Henningfield J.E. The development of a cocaine craving questionnaire. Drug and Alcohol Dependence 1993, 34:19-28.
36. Trotti A., Colevas A.D., Setser A., Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. Journal of Clinical Oncology 2007, 25:5121-5127.
37. Verthein U., Beck T., Haasen C., Reimer J. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized cross-over study. European Addiction Research 2014.
38. Wallin J., Sjövall J. Detection of adverse drug reactions in a clinical trial using two types of questioning. Clinical Therapeutics 1981, 3:450-452.
39. Woosley R.L. Drugs that prolong the QT interval and/or induce torsades de pointes; CredibleMeds™ Available at:, (Accessed 12 Oct 2013). http://www.crediblemeds.org/.
40. World Health Organisation Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence Retrieved from. http://www.who.int/substance_abuse/activities/treatment_opioid_dependence/en/.